There is some vague chatter on Wall Street today about Cephalon CEPH possibly being the target of a takeover. The suitors that have been mentioned in the past include Pfizer PFE and in particular Takeda Pharmaceutical.
Cephalon (CEPH) is trading well off of its lows for the day, but remains in negative territory. Currently the shares have shed 0.81% and are exchanging hands for $60.28. Even if an offer does not materialize, CEPH looks rather cheap at less than 8 times forward earnings and a PEG ratio of 0.83.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in